StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > it's not over just a start

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Jul 05, 2021 3:31pm

175 Views

Post# 33493765

RE:RE:it's not over just a start

Speaking of next quarter results, It will be interesting to see Q2.

Recall this from Q1:

The Company generated $2.5M in revenue from COVID testing for the quarter. Net loss for the quarter totaled $7.3M. To reflect the operations of the Company more clearly, management has prepared an analysis of EBITDA and Adjusted EBITDA in the MD&A. As disclosed in the MD&A, the adjusted EBITDA for the quarter was $193,000. As at March 31, 2021, the Company had $6.4 million in cash. The $4.9 million increased loss results from the $4.2 million impact of the revaluation of warrants,

The loss was mainly on paper and due to the revaluation of the warrants. So what happens now that the warrants price has dropped from last quarter and the Canadian dollar has increased. We are looking at a positive valuation. If Covid revenues are over $2 million again and add in any Aristote revenues we could very well see positive EBITDA again and a positive valuation with warrants.

We could be looking at an actual profit this quarter and a positive EBITDA that would garner some attention.

gojotv! wrote: The need for Covid testing is evident and ongoing. So will our revenues be. If SZLS revenues merely HOLD for the year, that'll be over $11Million dollars by year-end.
But, it's almost impossible for revenues to merely hold, because of the already-swelling travel boom. Revenues stand to double, or even triple from here. So, anyone with a third-grader's understanding of math can see that the stock price is poised to soar...
So, what could be holding it down?
Are there entities out there that have an interest in holding the price down, discouraging shareholders, and buying up this company on the cheap?
You bet there are.
Everyone knows this is a revenue gold mine.
Big Pharma doesn't want to get away from them.
And neither do I.
Thank-you, Mrs. Baldwin, for being such a great Grade 3 math teacher!
I have a huge advantage over the (extremely few) people selling their SZLS stock today, because you taught me simple multiplication!
GLTA locic-hounds and math fiends!

jp1989 wrote: https://www.lapresse.ca/international/europe/2021-07-03/covid-19-en-russie/cinquieme-jour-consecutif-avec-un-record-de-deces-quotidiens.php